The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma

On June 29, 2007 the first iPhone was released in the US and there was a feeling it would be an extraordinary, life changing product. It revolutionized how we interact with phones, more specifically smartphones, which now serve as an extension of our lives to what essentially amounts to an obligate symbiotic relationship. This product, called the iPhone 2G, was only the first iteration of many subsequent generations of iPhones. However, it came at a hefty price at $599 for the 8GB model. The development of chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM) and other malignancies is, in many ways, analogous to technological advancement that occurred with the iPhone creation.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research